Markus Müschen, MD, PhD

CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic overdrive.

Study reveals CD25 tunes tyrosine kinase signaling into a Goldilocks sweet spot, helping AML and ALL cells resist treatment and grow.